SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 30, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Cystic Fibrosis-related DiabetesCystic Fibrosis

Interventions

DRUG

Empagliflozin

Sodium glucose co-transporter 2 inhibitor

OTHER

Placebo Control

Trial Locations (1)

University of Minnesota, Minneapolis

All Listed Sponsors

lead

University of Minnesota

OTHER

NCT06149793 - SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes | Biotech Hunter | Biotech Hunter